Dr. James P. Krainson

Pulmonary Medicine | Sleep Medicine
12600 Sw 120th St, Suite 117, 
Miami, FL 
 (2321.5 mi)
12600 Sw 120th St, Suite 117, 
Miami, FL 
 (2321.5 mi)
OverviewInsuranceLocationsClinical Research

Overview

James Krainson is a Pulmonary Medicine specialist and a Sleep Medicine provider in Miami, Florida. His top areas of expertise are Asbestosis, Severe Acute Respiratory Syndrome (SARS), Excessive Daytime Sleepiness, and Narcolepsy.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Pulmonary Medicine
Sleep Medicine
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Locations

12600 Sw 120th St, Suite 117, Miami, FL 33186

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of Mepolizumab 100 mg SC as add-on Treatment in Participants With COPD Experiencing Frequent Exacerbations and Characterized by Eosinophil Levels (Study 208657)
Enrollment Status: Completed
Publish Date: December 11, 2024
Intervention Type: Biological, Drug
Study Drug: Mepolizumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Active_not_recruiting
Publish Date: September 19, 2024
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness
Enrollment Status: Completed
Publish Date: April 11, 2024
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab
Study Phase: Phase 2/Phase 3
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Enrollment Status: Completed
Publish Date: October 16, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
Enrollment Status: Completed
Publish Date: July 01, 2022
Intervention Type: Drug
Study Drugs: Bamlanivimab, Etesevimab, LY3853113 Anti-COVID-19 Antibody, VIR-7831 Anti-COVID-19 Antibody
Study Phase: Phase 2
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Blood Sample Collection in Subjects With Pulmonary Nodules or CT Suspicion of Lung Cancer or Pathologically Diagnosed Lung Cancer
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
2016-11: Blood Sample Collection in Subjects Participating in a Lung Cancer Screening Program
Enrollment Status: Completed
Publish Date: February 15, 2021
Intervention Type: Other
View 8 Less Clinical Trials

5 Total Publications

Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Effect of Subcutaneous Casirivimab and Imdevimab Antibody Combination vs Placebo on Development of Symptomatic COVID-19 in Early Asymptomatic SARS-CoV-2 Infection: A Randomized Clinical Trial.
Journal: JAMA
Published: January 14, 2022
Similar Doctors
Expertise in
3
conditions
Dr. Harneet K. Walia
Sleep Medicine | Pulmonary Medicine
Expertise in
3
conditions
Dr. Harneet K. Walia
Sleep Medicine | Pulmonary Medicine

Baptist Health Medical Group Physicians LLC

7400 Sw 87th Ave, Suite 100, 
Miami, FL 
 (5.0 mi)
305-275-8200
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Harneet Walia is a Sleep Medicine specialist and a Pulmonary Medicine provider in Miami, Florida. Dr. Walia is highly rated in 3 conditions, according to our data. Her top areas of expertise are Obstructive Sleep Apnea, Restless Legs Syndrome, Excessive Daytime Sleepiness, and REM Behavior Disorder. Dr. Walia is currently accepting new patients.

Naresh M. Punjabi
Expertise in
6
conditions
Dr. Naresh M. Punjabi
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine
Expertise in
6
conditions
Dr. Naresh M. Punjabi
Pulmonary Medicine | Sleep Medicine | Intensive Care Medicine

University Of Miami

900 Nw 17th St, Ableh/bpei, 
Miami, FL 
 (14.9 mi)
305-243-6857
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Naresh Punjabi is a Pulmonary Medicine specialist and a Sleep Medicine provider in Miami, Florida. Dr. Punjabi is highly rated in 6 conditions, according to our data. His top areas of expertise are Obstructive Sleep Apnea, Cerebral Hypoxia, Central Sleep Apnea, and Restless Legs Syndrome. Dr. Punjabi is currently accepting new patients.

Expertise in
26
conditions
Dr. Fernando A. Keller
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
Expertise in
26
conditions
Dr. Fernando A. Keller
Pulmonary Medicine | Intensive Care Medicine | Sleep Medicine
2623 S Seacrest Blvd, Suite 214, 
Boynton Beach, FL 
 (61.9 mi)
561-731-2269
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Fernando Keller is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Boynton Beach, Florida. Dr. Keller has been practicing medicine for over 46 years is highly rated in 26 conditions, according to our data. His top areas of expertise are Lung Metastases, Chronic Obstructive Pulmonary Disease (COPD), Asthma in Children, Asthma, and Endoscopy. Dr. Keller is currently accepting new patients.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile